Generate Biomedicines (GENB) Stock Price, News & Analysis

Company Overview

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules. Generate Biomedicines is advancing a pipeline of investigational medicines, including antibody and other protein therapeutics, with research programs spanning areas such as oncology, immunology and inflammatory diseases.

Founded with backing from Flagship Pioneering, Generate Biomedicines operates as a clinical-stage biotechnology company. Its programs remain under research and clinical development, and the company does not currently market approved medicines. Generate Biomedicines is headquartered in the United States and is developing therapies intended for potential use in global healthcare markets.

Key Stats

• Today's Range: $13.55 to $14.19
• 50-Day Range: $13.08 to $20.38
• 52-Week Range: $11.00 to $22.67
• Volume: 1.17 million shs
• Average Volume: 1.23 million shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.40
• Consensus Rating: Moderate Buy

Generate Biomedicines Stock Analysis - MarketRank™

Generate Biomedicines scored higher than 52% of companies evaluated by MarketBeat, and ranked 458th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Generate Biomedicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Generate Biomedicines has a consensus price target of $26.40, representing about 91.3% upside from its current price of $13.80.

Amount of Analyst Coverage

Generate Biomedicines has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Generate Biomedicines are expected to grow in the coming year, from ($2.29) to ($2.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Generate Biomedicines is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Generate Biomedicines is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.59% of the float of Generate Biomedicines has been sold short.

Short Interest Ratio / Days to Cover

Generate Biomedicines has a short interest ratio ("days to cover") of 7.24.

Change versus previous month

Short interest in Generate Biomedicines has recently decreased by 3.70%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Generate Biomedicines does not currently pay a dividend.

Dividend Growth

Generate Biomedicines does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.07

News Sentiment

Generate Biomedicines has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Generate Biomedicines this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for GENB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Generate Biomedicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Generate Biomedicines insiders have not sold or bought any company stock.

Percentage Held by Institutions

Generate Biomedicines has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GENB
• CIK: 2100782
• Web: www.generatebiomedicines.com
• Phone: (888) 469-0055
• Fax: N/A
• Employees: 312
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Generate Biomedicines: $26.40
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: +91.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.30
• Quick Ratio: 8.30

Sales & Book Value

• Annual Sales: $31.89 million
• Price / Sales: 55.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 128,350,000
• Free Float: N/A
• Market Cap: $1.77 billion
• Optionable: N/A
• Beta: N/A